Age-stratified clinical outcomes and adverse events in patients with metastatic castration-sensitive prostate cancer receiving triplet therapy with darolutamide, androgen deprivation therapy, and docetaxel
In this real-world cohort, triplet therapy showed substantial PSA declines and acceptable tolerability, with no significant differences in short-term efficacy or safety between patients aged <75 and ≥ 75 years. These findings suggest that chronological age alone should not preclude consideration of triplet therapy in appropriately selected patients.
Authors
- Hirofumi Morinaka
- Kiyoshi Takahara (ORCID: https://orcid.org/0000-0002-4766-2074)
- TERUO INAMOTO
- Kensuke Hirosuna (ORCID: https://orcid.org/0000-0002-9263-4929)
- Yuki Yoshikawa (ORCID: https://orcid.org/0000-0001-8834-5051)
- Kyosuke Nishio
- Tsuyoshi Morita
- TAKUYA TSUJINO
- Taisuke Jo (ORCID: https://orcid.org/0000-0003-4980-0589)
- Kazumasa Komura (ORCID: https://orcid.org/0000-0001-5082-3054)
- Moritoshi Sakamoto (ORCID: https://orcid.org/0009-0000-2053-0058)
- Taizo Uchimoto (ORCID: https://orcid.org/0000-0002-5200-9053)
- Atsushi Ichihashi
- Kazutoshi Fujita
- Wataru Fukuokaya
- Takafumi Yanagisawa
- Shunsuke Tsuzuki
- Heima Niigawa
- Kazuki Nishimura
- Haruhito Azuma
- Saizo Fujimoto
- Masanobu Saruta
- Atsuhiko Yoshizawa
- Keiichiro Mori
- Takahiro Kimura
- Yutaka Yamamoto
- Ryoichi Maenosono
- Fumihiko Urabe
Institutions
- Jikei University School of Medicine (JP)
- Kawasaki Medical School (JP)
- Hamamatsu University School of Medicine (JP)
- Fujita Health University Hospital (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2026-01-13
- DOI
- https://doi.org/10.1093/jjco/hyag011
- Primary Topic
- Prostate Cancer Treatment and Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00